The following collection of publications and resources contributes to the growing evidence of pharmacist impact on care in patients with substance use disorder. Publications included address pharmacist interventions provided across treatment settings ranging from community pharmacy based opioid risk identification and reduction strategies to comprehensive medication management via pharmacist collaborative practice agreements and prescribing privileges. Positions statements and documented practice models are included which highlight the value of pharmacists in this population. 

To jump to specific sections of interest, please select from one of the following:

a. General Substance Use Disorder Practice
   i. Outpatient
   ii. Inpatient and Residential

b. Opioid Use Disorder
   i. Outpatient
   ii. Inpatient and Residential

c. Overdose Prevention and Harm Reduction Services

d. Policy and Position Statements

e. Editorial/Commentary

*Designates Department of Veterans Affairs publication

General Substance Use Disorder Practice
Outpatient


- **Design:** Exploratory study of Wisconsin’s pharmacy laws which authorize pharmacists to provide a naltrexone injection service including semi-structured pharmacist interview (n=4)
- **Practices:** community pharmacists created infrastructures with naltrexone injection training, obtained CLIA waiver to administer rapid drug screen, created private space for administration, and established collaborative practice agreements with behavioral health practitioner or physician prescriber; n=1 pharmacist reported patients were referred by provider (80%) or treated as walk-ins (20%)
• **Conclusions:** Wisconsin laws and new partnership between community pharmacists, individuals, and prescribers highlight potential for community pharmacy in addressing OUD. Barriers included transportation, service infrastructure, reimbursement, and practitioner awareness and acceptance.


• **Design:** Retrospective chart review of N=143 pharmacist e-consults within a single VHA facility over a 2-year period.

• **Practices:** Pharmacist provided urine drug testing (UDT) electronic consultation (e-consult) service to assist providers with interpretation of this useful yet complex clinical tool. Completed e-consults provided either education-based (informative) or action based (decisive) recommendations.

• **Outcomes:**
  - 190 UDT results classified as expected, unexpected, or not necessarily inappropriate based on prescription profile at time of urine immunoassay test.
    - >70% of cases with no confirmatory testing ordered by requesting provider
    - 32% of cases classified as “unexpected” identified the presence of an illicit substance
    - 50% of cases classified as “unexpected” resulted in pharmacist recommendation for the requesting provider to take immediate action; timely documentation of post-consultation action by requesting provider was only present in 32% of cases.


• **Design:** interrupted time series design evaluated level and rate of change in monthly percent patients with alcohol use disorder (AUD) received naltrexone, acamprosate, disulfiram, or topiramate across multiple Veterans Health Administration (VHA) sites (N=37) following implementation of an academic detailing program.
  - Control group: 20-month post-implementation and 16-month pre-implementation outcomes were compared within participating study sites (N=37) and separately to all remaining VHA control facilities (to verify changes did not mimic secular trends for other facilities).

• **Practices:** clinical pharmacists provided academic detailing related to AUD pharmacotherapy to various staff including psychologists, psychiatrists, nurses, social workers, clinical pharmacists, primary physicians, clinical managers and other administrators.

• **Outcomes:**
  - Percent patients with AUD with study medication increased 4.9% pre-implementation to 8.3% post-implementation at intervention sites (p<0.05)
  - Pre-to-post implementation increase in prescribing rate slope within intervention sites compared to pre-implementation slope was significantly positive (p < .0001); change in slope was significantly less for all other VHA sites (control) than the intervention sites (p <.001).


• **Design:** descriptive review of process through which board-certified psychiatric pharmacists may develop and implement a Collaborative Drug Therapy Management (CDTM) agreement within a community treatment center for mental health and substance abuse disorders.
• **Practices:** Outpatient clinical psychiatric pharmacy services involving independent patient appointments included but were not limited to assessment and management of polypharmacy, long-acting injectable antipsychotics, suspected nonadherence, medication reconciliation, transitions of care services, therapeutic drug monitoring, and antipsychotic metabolic monitoring.

• **Outcomes/Conclusions:** Key considerations for successful implementation and expansion of outpatient psychiatric clinical pharmacy services include ensuring collaborating provider/facility administration understanding of psychiatrist pharmacist clinical competence, potential positive influence on patient outcomes and cost savings, federal and state laws governing CDTM, and third-party billing mechanisms.


• **Summary:** The MH clinical pharmacist practitioner (CPP) serves in many key roles to improve patient-centered care and medication outcomes by supporting the needs of the MH team, patients, and caregivers in areas of comprehensive medication management. MH CPP providers are integrated as MH providers in general and specialty MH clinics, behavioral health clinics embedded in primary care, residential rehabilitation facilities, specialty MH programs, and in inpatient MH units to improve access, quality, and safety. Overall, the MH CPS provider improves access to care, clinical outcomes, and safety when deployed as direct patient care providers on Veterans Affairs (VA) interprofessional care teams. VA MH clinical pharmacy practice continues to demonstrate what the MH CPS provider, practicing at the top of their license, can achieve as a core member in MH team-based care.


• **Design:** retrospective observational cohort

• **Practice:** pharmacist-led substance use disorder (SUD) transitions of care telephone clinic aims to improve post-discharge continuity of MOUD/MAUD for patients initiating buprenorphine/naloxone and extended-release naltrexone injections during inpatient admission

• **Outcomes:**
  o N=150 patients; n=54 initiated MOUD/MAUD during inpatient admission and received post-discharge SUD transitions of care service (intervention group); n=96 initiated MAUD/MOUD during inpatient admission but were not referred for services
  o Primary endpoint of combined 1- and 3-month MOUD/MAUD retention rates as measured by a continuous, multiple-interval measure of medication acquisition (CMA) of ER naltrexone and BUP/NAL for the intervention group (n=54) vs. control group (n=96)
    ▪ 1-month: 77.3% vs. 56.8%, p = 0.004; 3-month: 71.4% vs. 48%, p = 0.0002
  o statistically and clinically significant improvements in MOUD/MAUD retention rates for patients enrolled in a pharmacist-led SUD transitions of care telephone clinic


• **Design:** Descriptive analysis
**Practices:** Pharmacist led management of pharmacotherapy for AUD in jail setting; the pharmacist attended daily alcohol detoxification assessments; identified and assessed patients at high risk of severe withdrawal; and initiated, modified, and discontinued withdrawal medication for selected patients

**Outcomes:**
- 1263 patients admitted to Alcohol and Drug Detoxification Unit ADU during the study; 282 patients assessed by the pharmacist
- Pharmacist medication intervention occurred in 148 patients
- 48 patients transferred to an acute care facility
- Zero alcohol detoxification related patient deaths occurred during the study


**Design:** Descriptive review of state and federal district (N=51) policy changes and deliberations related to gabapentin.

**Practices:** summarize state-level gabapentin misuse-related policies in the US through September 1, 2021, discuss the benefits and risks of current measures, and highlight gaps in national response

**Outcomes/Conclusions:**
- n=22 states and federal districts (43.1%) tightened regulation; n=15 states (29.4%) enrolling gabapentin into their PDMP and 7 states (13.7%) re-classified gabapentin as a C-V; 2 states (3.9%) are considering tightening their regulation.
- state interventions decreased quantity dispensed but did not address patient outcomes or reduce harm. Harm-reduction informed public health policy is needed to impact patient outcomes.


**Design:** descriptive review

**Practices:** development of Vulnerable Veteran Innovative Patient-Aligned Care Team (VIP) Initiative at the Veterans Affairs (VA) Salt Lake City Health Care System which uses interdisciplinary primary care (IPC) to improve health care access for Veterans with SUDs; team members include primary care providers with certification in addiction medicine (n=3), an x-waivered internist (n=1), nurse care manager (n=1), mental health pharmacists specializing in SUD treatment (n=2), mental health nurse (n=1), and social worker (n=1)

**Conclusions:**
- Primary care provides a novel environment to deliver addiction services and address social determinants of poor health for vulnerable patients
- 60% of patients seen by VIP have a history of substance use disorders or homelessness vs. 15% of patients managed in other PACTs
- VIP patients with OUD: 55% receive buprenorphine vs. only 22% patients within other PACTs during two-year time interval

- **Design:** Interrupted time series study
- **Practices:** Vulnerable Veteran Innovative Patient-Aligned Care Team (VIP) Initiative at the Veterans Affairs (VA) Salt Lake City Health Care System uses interdisciplinary primary care (IPC) to improve health care access for Veterans with SUDs; team members include primary care providers with certification in addiction medicine (n=3), an x-waivered internist (n=1), nurse care manager (n=1), mental health pharmacists specializing in SUD treatment (n=2), mental health nurse (n=1), and social worker (n=1).
- **Conclusions:**
  - IPC enrollment (N=994) was associated with overall reductions in ED, inpatient, and behavioral health visits (p's<0.001) and increases in primary care (p's<0.001)
  - Reductions most significant in those with history of high ED use (n=265): ED, inpatient, and behavioral health visits decreased after enrollment (level change incidence rate ratios [IRRs]=0.57-0.69) and continued to decline over time (post-enrollment IRRs=0.80-0.88)

Inpatient and Residential


- **Design:** descriptive review of pharmacist intervention with specialized education on alcoholism and addiction
- **Practices:** Pharmacists provide pharmaceutical services to meet the medical needs of patients during detoxification; development of detoxification protocols for management of withdrawal from drugs of abuse; education of patients and their families, other clinical staff members, and pharmacy students about the pathophysiology of addiction, treatment options, and the foundations of recovery; medication and addiction counseling; and multidisciplinary team support of recovery. The pharmacist employed at this hospital spends about 70% of her time with pharmaceutical services and 30% with counseling services.
- **Outcomes/Conclusions:** Pharmacists in a chemical-dependency rehabilitation program have a unique opportunity to affect positively the physical and emotional health of recovering individuals by taking on responsibilities beyond traditional pharmacy practice.


- **Design:** descriptive review
- **Practices:** pharmaceutical services within the Canadian Centre for Addiction and Mental Health provided by approximately 30 pharmacists with expertise in addictions and mental health
- **Conclusions:** Pharmacist provided a range of clinical and medication management services and play an important role in the education and training of students, hospital staff, clients, and the general public. Pharmacists may participate in policy development and dissemination and in research. CAMH pharmacists work within multidisciplinary health teams (which also include, among others, psychiatrists, other physicians, nurses, occupational therapists, social workers, dieticians, and recreational therapists) and the patient population.

- **Design:** Descriptive report-Development of substance use intervention team (SUIT) and related outcomes
- **Practices:** The SUIT program provides inpatient consultation services as well as medical and behavioral clinic visits to transition patients to long-term treatment and is comprised of physicians, nurse practitioners, a clinical pharmacist, social workers, and a nurse. The medical center initiated screening efforts in tandem with its interdisciplinary team and clinic. The team would attempt to start appropriately selected patients with SUD on medications for SUD while hospitalized. The clinical pharmacist rounds with the inpatient SUIT service, counsels patients, and oversees the inpatient and outpatient medication use process.
- **Outcomes/Conclusion:** From January- December 2018, 87.2% of patients admitted to the hospital received initial SUD screening. Of the patients who screened positive, 1,400 received a brief intervention by a unit social worker; the SUIT service was consulted on 880 patients, and multiple medications for SUD were started during inpatient care. The SUIT service can serve as a model for programs working to implement SBIRT and SUD treatment services.


- **Design:** single-center, single-site, retrospective, observational cohort study
- **Practices:** evaluation of MAUD/MOUD related outcomes 12 months before and after addition of a psychiatric CPP as the primary prescriber member of an inpatient addiction consult team
- **Conclusions:**
  - MAUD/MOUD initiation rates prior to hospital discharge increased in CPP intervention group compared with the historical control group (26.3% vs 4%, \( P < .0001 \))
  - introduction of a CPP to an inpatient addiction triage team was feasible, well received by interprofessional team members, and required limited additional resources

**Opioid Use Disorder**

**Outpatient Setting**


- **Design:** Descriptive practice review
- **Practices:** Pharmacist provided dispensing, drug information, staff and patient education, pharmacotherapeutic evaluation and management services, and served as the medical clinical coordinator within an outpatient methadone maintenance and chemical dependence clinic.
- **Outcomes/Conclusions:**
  - The pharmacist's knowledge of pharmacotherapy, drug products, and skill in assessing and managing problems related to substance use increased access of physicians and nurses for other patient-care activities and enhanced behavioral counselors’ understanding of pharmacologic aspects patients with substance use disorder.
Inclusion of a pharmacist in the chemical-dependency healthcare team was accepted, valued, and recommended by clinic staff.


- **Design:** Descriptive review of impact of completion of “The Change Book” training (Addiction Technology Transfer Centers) completed by 51 practitioners (17 physicians, 4 pharmacists, 2 nurse practitioners, 28 drug abuse counselors/administrators) from 7 Oregon counties on development of buprenorphine services
- **Practices:** Opioid Medication Initiative for Rural Oregon Residents (OMIROR) sought to improve access and quality of opioid dependence treatment through development of county teams which included a pharmacist to work collaboratively with physicians and drug treatment services.
- **Outcomes:**
  - Pre-post measure of attitudes and beliefs toward use of buprenorphine suggested significant improvements in attitude after training (especially among counselors)
  - 8 months post training: 10 of 17 physicians received buprenorphine waivers; 29 patients were in treatment with six of the physicians


- **Design:** telephone survey of N=345 high-dosage buprenorphine (HDB) prescribers
- **Practices:** factors associated with general practitioner collaboration with dispensing pharmacists on management of patients receiving HDB was investigated
- **Outcomes:**
  - Only 54% of general practitioners reported collaborating with dispensing pharmacists in management of HDB patients (collaboration independently related to addiction training, favorable opinion of maintenance treatment, long experience in HDB management, and participation in specialized medical network)
  - Implementation of physician-pharmacist collaboration may require additional addiction medicine training for general practitioner and encouragement to participate in medical networks


- **Design:** Descriptive review of clinical psychiatric pharmacist integration into an interdisciplinary team of psychiatrists and addiction therapists in a VA outpatient buprenorphine clinic
- **Practices:** the pharmacist devotes approximately ten hours per week to services including medication dispensing, monitoring (labs, random medication counts), patient counseling, and maintains weekly records of dosing, refill dates, and urine toxicology results.
- **Outcomes:**
  - Following psychiatric pharmacist integration, patient enrollment in buprenorphine clinic and patient satisfaction with outpatient pharmacy experience increased; pharmacy wait times and early refills decreased


- **Design:** prospective observational review of N=45 outpatients treated with buprenorphine in urban academic primary care clinic affiliated with tertiary care hospital
• **Practices:** the pharmacist case manager with expertise in pain management conducted buprenorphine inductions and all follow-up medication visits under the supervision of an x-waivered psychiatrist

• **Outcomes:**
  - 6-month treatment retention: 55.0% (n=25)
  - Proportion of aberrant urine toxicology results and craving scores significantly decreased from baseline to 6 months (p<0.01)
  - PCP confidence treating opioid dependence in primary care increased significantly from baseline to 18-months post-implementation (p<0.01)


• **Design:** Retrospective chart review to describe impact of pharmacist-patient interactions on buprenorphine patient outcomes in a suburban health department program (N=12) over a 12-month period

• **Practices:** A Board-Certified Psychiatric Pharmacist provided buprenorphine intake and follow-up appointments with physician collaboration and co-signature

• **Outcomes:**
  - N=12 patients completed full intake with 135 total follow-up appointments
  - 6-month retention rate=100%; 12-month retention rate = 73% (higher than previously published studies)
  - n=127 (98%) urine toxicology screens positive for buprenorphine; n=114 (88%) positive for buprenorphine and negative for illicit opioids; no suspected incidences of diversion
  - Estimated pilot program cost savings compared to average community cost without pharmacist involvement = $22,000; projected future cost savings with transition of all health department buprenorphine patients to this model = $63,000/year


• **Design:** descriptive review of collaborative care model for buprenorphine management in a county behavioral health service for homeless patients

• **Practices:** Psychiatric pharmacist provided comprehensive medication management for buprenorphine office and home induction and maintenance services with psychiatrist collaboration

• **Outcomes:** not reported


• **Design:** systemic review of primary care-based medication assisted treatment interventions for opioid use disorder aimed to identify program structures and processes associated with improved patient outcomes to guide future policy and implementation efforts

• **Practices:** Pharmacist roles across practices varied and included dispensing, providing clinical care management services, and clinical appointments for medication management for MAT for OUD.

• **Outcomes:**
  - Key program factors associated with success included presence of integrated clinical teams with clinical care managers who were often advanced practice clinicians (i.e. nurses and pharmacists); use of patient care “agreements”; and use of home induction models.
  - Clinical pharmacists can be utilized for complex medication dosing and management scenarios

- **Design:** descriptive review of office-based opioid treatment (OBOT) implementation by an interdisciplinary team including a physician champion, clinical pharmacist, nurse practitioner, and licensed clinical social worker
- **Practices:** Pharmacist developed program policies and procedures, patient care agreements, and medication treatment protocols
- **Outcomes/Conclusions:**
  - Having a “core interdisciplinary team is essential”
  - In the first year, 5 faculty physicians prescribed buprenorphine for 14 maintenance patients.
  - In the second year, 11 additional physicians were trained, and services expanded to include buprenorphine induction services.

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients with Opioid Use Disorder: CTN 0075 (Pharm-OUD-Care). Duke University. 2017; ClinicalTrials.Gov (in development)

- **Design:** open-label, single arm, pilot study of pharmacist-administered buprenorphine/naloxone maintenance care
- **Practices:** examines the feasibility and acceptability of transitioning office-based buprenorphine treatment of opioid use disorder from physicians to pharmacists.
- **Outcomes/Conclusions:** pending; results will inform the development of a future multi-site randomized clinical trial


- **Design:** descriptive review of a Screening, Brief Intervention, and Referral to Treatment (SBIRT) community pharmacist program
- **Practices:** Pharmacist provided brief patient counseling including motivational interviewing principles aimed at enhancing motivation for eliminating or reducing alcohol and/or opioid misuse; enhancing motivation to access harm reduction and/or behavioral health services; and provided “ward handoffs” to other healthcare managers for treatment services.
- **Outcomes/Conclusions:** community pharmacists should be trained and activated in conducting public health campaigns and riving efforts to reduce the Opioid Crisis


- **Design:** Quality improvement project
- **Practices:** A psychiatric clinical pharmacy specialist served as an internal facilitator by visiting with rural outpatient clinics’ frontline staff/managers, providing medication for opioid use disorder (MOUD) education, supporting psychiatry providers, and briefing hospital leadership. The goal was to increase availability of MOUD to Veterans, focusing on tele-prescribing buprenorphine to rural sites.
- **Outcomes/conclusions:**
  - N=12 Veterans were transferred to the rural telehealth buprenorphine clinic (home inductions: n=2; monitored induction at CBOC: n=4; transferred from another facility once tele-buprenorphine was made available: n=6).
  - n=9 (75%) remained on buprenorphine for a six month time period after beginning buprenorphine telehealth services.
Overall, implementing tele-prescribing was negotiated with stakeholders at the target clinics and operationalized in a toolkit to guide future efforts.


- **Design:** Retrospective chart review
- **Practices:** An emergency physician and pharmacist implemented a protocol using buprenorphine for the treatment of patients with opioid withdrawal at an academic, Level I trauma center. Patients included in this study were those in the ED for whom buprenorphine was administered to treat opioid withdrawal during an 18-month period
- **Outcomes/conclusions:**
  - N=77 patients who received buprenorphine, n=33 (43%) did not present with the chief complaint of opioid withdrawal; 74% last used heroin and presented in moderate opioid withdrawal
  - n=1 case of precipitated withdrawal occurred after buprenorphine administration
  - n=23 (30%) of patients received outpatient follow-up
  - Results underscore the safety, effectiveness, and feasibility of ED-initiated buprenorphine administration.

Gordon AJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Substance Abuse. 2020; 41(3), 275-282.*

- **Summary:** In the Spring of 2018, the VHA initiated the Stepped Care for Opioid Use Disorder, Train the Trainer (SCOUTT) Initiative to facilitate access to MOUD in VHA non-SUD care settings. The SCOUTT Initiative’s primary goal is to increase MOUD prescribing in VHA primary care, mental health, and pain clinics by training providers working in those settings on how to provide MOUD and to facilitate implementation by providing an ongoing learning collaborative. The VHA Office of Mental Health & Suicide Prevention (OMHSP) collaborated with a wide representation of VHA stakeholders in originating, planning, and implementing the SCOUTT Initiative, including leaders representing (among others) national pain, primary care, mental health, SUD specialty-care, primary care mental health integration, pharmacy, nursing, and education services. These leaders formed the multidisciplinary Planning Committee for the SCOUTT Initiative that began meeting monthly in January 2018 and continues to meet today.


- **Design:** Descriptive reports – overview of a clinical pharmacist care manager (CPCM) model for medications for OUD treatment
- **Practices/Description:** At the Minneapolis Veterans Affairs Health Care System the CPCM model for medications for OUD (MOUD) was identified as a care model that would address patient and facility barriers to effective OUD treatment. Pharmacists were integral in program development and implementation and served as the main care providers. An interim evaluation of the program established that the proportion of patients with OUD receiving MOUD had increased, with use of the program resulting in treatment of 109 unique patients during 625 visits. Key program implementation facilitators included the facility leadership establishing increased use of MOUD as a priority area, identification of a physician champion, and a history of successful expansion of clinical pharmacy specialist practice within the VA system. Implementation barriers included factors related to provider
engagement, patient identification, and program support. The CPCM model of provision of MOUD expanded the pharmacist role in buprenorphine management.


- **Design:** Nonrandomized, single-arm, open-label feasibility trial investigating the feasibility/acceptability of a new collaborative care model involving buprenorphine-waivered physicians and community pharmacists.
- **Practices:** Three office-based buprenorphine treatment (OBBT) clinics and three community pharmacies in the United States (total of six physicians and six pharmacists involved. After screening, eligible patients' buprenorphine care was transferred from their OBBT physician to a community pharmacist for 6 months.
- **Outcomes/Conclusions:**
  - \( n=71/76 \) of eligible participants enrolled into the study
  - High rates of treatment retention (88.7%) and adherence (95.3%) at 6-months
  - Opioid-positive urine drug screens among complete cases at 6-months = 4.9% (3/61).
  - Pharmacists used PDMP at 96.8% of visits.
  - no opioid-related safety events
  - Positive ratings of satisfaction were found among patients, physicians, and pharmacists


- **Design:** Quality improvement looking at a physician-pharmacist collaborative practice models (PPCPM) implementation for management of patients on MOUD with buprenorphine/naloxone
- **Practices:** A PPCPM for management of patients on MOUD with buprenorphine/naloxone was piloted in an outpatient substance use disorder clinic. Approximately 4 hours per week were dedicated to physician-pharmacist collaborative medical appointments for a 5-month trial period. The pharmacist met with the patient first and then staffed the case with the collaborating psychiatrist. Descriptive data from PPCPM appointments was collected and compared to data from psychiatrist-only appointments.
- **Outcomes/Conclusions:** 25 patients were seen over 44 appointments (estimated 33 hours of psychiatrist time saved). Average initial and end buprenorphine doses, urine drug screen (UDS) results, and mental health (MH) medication interventions were similar between patients seen in PPCPM appointments compared with those seen in psychiatrist-only appointments. Collection of UDS, identification and management of MOUD adherence issues, other service referrals, and medication reconciliation intervention were more frequent in PPCPM appointments. Overall, implementation of a PPCPM allowed for provision of a similar level of care regarding MOUD and MH-related medication management while saving psychiatrist time.


- **Resource type:** technical brief intended to assist healthcare policy makers, providers, and patients in making informed decisions and therefore improving quality of healthcare services
• **Summary**: outlines and promotes integration of pharmacist-based management strategies into MAT models of care in primary care settings

**Project ECHO: Medication Assisted Treatment Clinic. University of Nevada, Reno School of Medicine**

• **Resource type**: telehealth consultation resource to support healthcare providers in providing care to underserved areas

• **Summary**: multidisciplinary MAT team includes pharmacist, physician, nurse, physician assistant and social worker members focusing on mentoring and supporting providers who are currently or interested in becoming Medication Assisted Therapy (MAT) certified

**Geisinger Staffing Model for MAT for Opioid Use Disorder**

• **Resource type**: practice model describing outpatient multidisciplinary MAT program within not-for-profit community healthcare system led by board certified addiction physicians with a case management team, an addiction-trained clinical pharmacist, advanced practitioners, and administrative support

• **Conclusions**:
  o Roles and responsibilities of the addiction-trained pharmacist when conducting initial and follow-up visits included education related to SUD diagnosis and appropriate level of care comprising medication and behavioral interventions; monitoring of state controlled substance database; buprenorphine induction and follow-up assessment of efficacy, adherence, and tolerability; ordering and assessment of urine toxicology and other laboratory values; and referral to other medical, psychological, and/or social services as indicated.

**Indian Health Service (IHS) Naltrexone XR Collaborative Practice Agreement Policy**

• **Design**: Policy/protocol description

• **Practices**: single IHS facility protocol for pharmacist management of naltrexone XR injection for alcohol or opioid use disorder in conjunction with outpatient substance use disorder behavioral interventions

• **Conclusions**:
  o Pharmacist provided comprehensive medication management of naltrexone XR injection upon provider referral including initiation and follow-up face-to-face visits; patient education; assessment of adherence and efficacy; ordering and assessment of urine drug screen, vitals, and other labs/tests; use of measurement-based care (e.g. PHQ-9, COWS)

Pals H, Bratberg J. Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder [published online ahead of print, 2022 Mar 11]. *J Am Pharm Assoc (2003)*. 2022;S1544-3191(22)00078-4. doi:10.1016/j.japh.2022.03.006*

• **Design**: Descriptive review of a pharmacist-psychiatrist collaborative practice

• **Practice**: Tomah Wisconsin VA hired CPPs with prescriptive authority for management of SUD and comorbid mental health conditions. These newly hired pharmacists established a collaborative practice agreement with X-waivered psychiatrists to manage buprenorphine for patients with OUD.

• **Outcomes/conclusions**:
  o Of N=60 patients receiving care for management of OUD at the Tomah VA, n=28 were seen for induction of buprenorphine same-day by CPP compared to historical wait time of 5.8 day (inpatient) to 6.1 day (outpatient) prior to CPP involvement
  o This innovative practice demonstrated an improvement in access to OUD treatment, and decreased psychiatrist workload burden.

- **Design**: Case Series
- **Practice**: Residents of a Shelter In Place (SIP) hotel with diagnosis of OUD were prescribed buprenorphine from an on-site provider. Clinical pharmacists hand-delivered buprenorphine to SIP residents to increase buprenorphine initiation and engagement.
- **Conclusions**: The combination of on-site medical providers with a clinical pharmacist delivering buprenorphine is possible and has the potential to increase access to care for OUD to those with marginal housing.


- **Design**: qualitative design
- **Practices**: focus group of student pharmacist at the University of Tennessee College of Pharmacy to investigate pharmacy student’s perspectives on pharmacists as providers of methadone-based MOUD treatment
- **Conclusions**: student pharmacists desire an active and larger role in the care of patients managing opioid use disorder; findings indicate students perceive less stigma toward OUD than currently practicing pharmacists; pharmacy curriculum should emphasize skills and knowledge related to medication for opioid use disorder management


- **Design**: interrupted time series design
- **Practices**: Primary care, pain, and mental health clinics in the VA health care system (n = 35) located at n=18 intervention facilities were compared to nonintervention comparison clinics (n = 35) following Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) implementation; SCOUTT teams consisted of prescribers, nurses, behavioral specialists, and pharmacists (study period: September 2017-2019 with implementation date September 2018)
- **Conclusions**:
  - N=7488 patients were seen in SCOUTT intervention clinics
  - Patients treated with MOUD per clinician in intervention clinics saw greater increases before to after SCOUTT implementation compared with comparison clinics (incidence rate ratio, 1.50; 95% CI, 1.28-1.77)
  - Implementation of MOUD services in primary care, mental health, and pain settings increases access to MOUD

- Design: anonymous survey to clinicians and leadership from study clinics
- Practices: interdisciplinary teams of clinic providers (including pharmacists) and leadership from primary care, pain, and mental health clinics at n=18 VA medical facilities participating in national SCOUTT program received invitations to complete an anonymous survey prior to intervention launch (baseline) and at 12-month follow-up to determine impact of SCOUTT intervention to increase MOUD delivery on changing providers' perceptions about MOUD over the first year of implementation.
- Conclusions:
  - Survey response rates: baseline 57.1% (56/98) and follow-up 50.4% (61/121)
  - Perceptions about MOUD generally were positive
  - Targeted education and planning strategies did not improve providers' and clinical leaders' perceptions of MOUD over time (53.7% affirmed clinic providers wanted to prescribe MOUD at baseline vs. similar responses at follow-up (34.5 vs. 52.4%)
  - Strategies that improve leaders' prioritization and support of MOUD and address time constraints related to delivering MOUD may increase access to MOUD in non-substance use treatment clinics.


- Design: descriptive review
- Practices: the VA Connecticut HCS SCOUTT team consisted of VISN leadership (in primary care, mental health, and addiction care), pharmacists, and a team of health care practitioners (HCPs) from step-2 clinics (including 2 addiction psychiatrists, and an advanced practice registered nurse, a registered nurse specializing in addiction care), and a team of HCPs from prospective step-1 clinics (including a clinical psychologist and 2 primary care physicians); Key interventions were to obtain leadership support, increase waivered prescribers, and develop processes and tools to enhance prescribing
- Conclusions:
  - MOUD receipt before and after 1 year of SCOUTT implementation: 4% increase from 552 (44%) to 582 (48%) (P = .04)
  - Number of waivered prescribers increased from 67 to 131; number of buprenorphine prescribers increased from 35 to 52 over a 6-month span; percentage of health care practitioners capable of prescribing within the electronic health record increased from 75% to 89% (P = .01)


- Design: qualitative interviews of clinicians and ethnographic observation of planning meetings
- Practices: evaluation of planning, design and implementation of a primary care-based buprenorphine clinic and e-consult service to expand access to MOUD within one health care system; interview subjects included clinical pharmacists, physicians, and RNs
- Conclusions:
a self-appointed local team consisting of primary care clinicians, clinic manager, SUD clinic specialist, and clinical pharmacist developed and built widespread support for new approaches to care delivery that were tailored to local needs and well-positioned for sustainability over time.

- collaboration with a clinical pharmacist with an emphasis on the trainee experience (pharmacy resident) enabled primary care to institute a dedicated clinic offering buprenorphine to patients to expand access to buprenorphine in a primary care setting

Inpatient and Residential


- **Design:** Qualitative study
- **Practices:** 6 Focus groups and 8 key informant interviews by patients who received care from pharmacists, social workers, nurses, hospitalists, or addiction consultation service workers (ACS) during their hospitalization to understand facilitators and barriers to hospital-based OUD treatment initiation and continuation from the perspective of patients with OUD and from hospital-based providers.
- **Conclusions:** Identified important ways to facilitate an increase and continuation of medications for OUD in hospitals including expanding access to in-hospital addiction expertise, greater use of opioid agonist treatment to manage opioid withdrawal, and provision of low-threshold OUD treatment.


- **Design:** Practice research report–retrospective cohort analysis
- **Practices:** This report compared rates of MAT, and OUD-related ED visits and/or hospital admissions within 1 year, between Veterans with OUD who completed inpatient rehabilitation prior to implementation of a series of group sessions designed to engage intrinsic motivation to change behavior surrounding opioid abuse and provide education about MAT (the control group) and those who completed rehabilitation after implementation of the education program (the intervention group). A post hoc, multivariate analysis was performed to evaluate possible predictors of MAT use and ED and/or hospital readmission. Groups were led by existing staff, including psychologists, social workers, and a clinical pharmacy specialist.
- **Outcomes:** 158 patients were included (95-control group vs 63-intervention group. Rates of MAT were 25% (24/95) and 75% (47/ 63) respectively (P < 0.01). Opioid series participation and MAT use were independently associated with decreased rates of OUD-related ED visits and/or hospital admission (hazard ratios of 0.16 [95% CI, 0.06-0.44] and 0.32 [95% CI, 0.14-0.77], respectively) within 1 year after rehabilitation completion. Overall, focused OUD-related education in a substance abuse program for veterans with OUD increased rates of MAT and was associated with a decrease in OUD-related ED visits and/or hospital admission within 1 year.

• **Design**: Feasibility Study

• **Practices**: Pharmacist-led screening of all patients receiving current opioid therapy for opioid stewardship. EHR identified all opioid, antidepressant, and benzodiazepine administrations within the previous 24 hours, and pertinent family and social history risk factors for OUD and OIRD.

• **Outcomes**:  
  - Chart reviews were completed on patients identified as high risk for OUD or OIRD: if MME (morphine milligram equivalents) was 90 or greater, or if patient received 4+ “as needed” opioid doses in last 24 hours.
  - Patients identified per day to receive stewardship: mean of 13
  - Potential interventions per day: mean of 18.6

**Overdose Prevention and Harm Reduction Services**


- **Design**: Descriptive review of pharmacist-based interventions to mitigate harm from opioid use disorder within the Indian Health Service (ISH).

- **Practices**: Pharmacists’ clinical role range from individual consultation appointments to full prescriptive authority for controlled substances. Pharmacists collaborated with buprenorphine prescribers to coordinate comprehensive patient care, contribute to provision of buprenorphine tele-medicine services, and manage depot naltrexone injection therapy.

- **Outcomes/Conclusions**: Pharmacists within IHS augmented services to increase access to MAT for American Indians and Alaska Natives, increased access to naloxone for opioid overdose reversal, and developed a comprehensive training program and program measurement tools for law enforcement officers (used to train n=350 officers in 6 districts and conduct a mass naloxone dispensing initiative).


- **Design**: descriptive review of implementation of pharmacist-led naloxone clinic in a pain management population within a family medicine clinic

- **Practices**: Pharmacist identified potential naloxone candidates via chart review, provided education to patient and/or identified caregiver, and naloxone prescriptions.

- **Outcomes/Conclusions**:  
  - During the first 6 months of clinic operations, 49 patients identified a “at risk for opioid overdose”; pharmacists educated 84% (n=41) of identified patients and confirmed 69% had filled a naloxone prescription
  - Pharmacist education sessions were completed as follows: 61% (n=25) during physician visit; 27% (n=11) during pharmacist-specific appointment; 12% (n=5) via telephone


- **Design**: descriptive, retrospective review
• Practices: identify primary care veterans at highest risk for serious opioid-related adverse events using the Risk Index for Overdose and Serious Opioid-Induced Respiratory Depression (RIOSORD) and offer rescue naloxone kits by telephone-based outreach

• Outcomes/conclusions:
  o n = 38 (92.7%) of patients identified as high risk within 3-month period reached by telephone;
    n=26 (63.4%) of those reached agreed to naloxone prescription
  o pharmacist-led telephone-based outreach is a viable option for distributing naloxone to high-risk populations using an opioid related risk stratification tool


• Design: retrospective chart review of naloxone related outcomes of a pharmacist-led clinical video telehealth (CVT) naloxone education group clinic vs. all other clinics at a Veterans Affairs Medical Center

• Practices: 1 Board Certified Psychiatric Pharmacist provided weekly naloxone groups including overdose prevention education and naloxone prescription via scope of practice simultaneously via CVT to urban and rural veterans across 2 main campuses and 4 community-based clinics. Patients were identified by clinic pharmacist via population management tools or referred by the opioid prescriber.

• Outcomes/Conclusions: 6-months post-implementation
  o Substance use disorder population trended toward lower rates of prescribing through the CVT clinic compared to all other clinics (21.4% vs 31.9%; P = .0821)
  o Patients identified by CVT clinic pharmacist more likely to have concomitant opioid benzodiazepine prescription (69.1% vs. 34.4%, p<0.001)
  o Naloxone CVT group clinic is an efficient strategy to extend services to high-risk patients beyond urban areas with 1 pharmacist prescribing 21.2% (n=84) of all facility naloxone during study period


• Design: Single-cohort pre- and post-intervention study

• Practices: Pharmacists imbedded in a primary care clinic educated clinical staff regarding naloxone, created quick links within the electronic health record for ease of prescribing, identified patients on chronic opioid therapy for pain who met criteria for naloxone (e.g. MED>50mg, concurrent benzodiazepine, substance use disorder, history of overdose), and educated patients.

• Outcomes/conclusions:
  o Increased naloxone chronic opioid therapy co-prescribing [3.4% to 372% (p=0.0001)]
  o Interventions by embedded clinical pharmacist helped to overcome common barriers to naloxone access.


• Design: Quasi-experimental, nonrandomized interventional study

• Practices: 5 outpatient pharmacists affiliated with an academic medical center provided patient-specific education regarding respiratory depression and overdose risk factors and offered prescription naloxone per North Carolina state health director order at initial visit
• **Outcomes/conclusions:** Pharmacist-driven intervention was associated with an increase in naloxone dispensing; of 38 eligible patients, n=2 naloxone prescriptions dispensed pre-implementation vs. 11 post-implementation (n = 0.007)


• **Design:** randomized control trial

• **Practices:** Patients who screened position for prescription opioid misuse using the Prescription Opioid Misuse Index were assigned to either standard medication counseling (SMC) by pharmacist or SMC plus brief motivational intervention-medication therapy management (BMI-MTM) [8-weekly sessions by pharmacist].

• **Outcomes/conclusions:**
  - High level of agreement among BMI-MTM participants for satisfaction per patient survey; at 3 months, patients who underwent BMI-MTM (n=15) had greater improvements in Opioid Misuse Index, pain (Short Form-36), and depression scales (PHQ-9) compared to SMC (n=17)


• **Design:** survey of Ohio community pharmacists and patient acceptance of pharmacy-based opioid interventions.

• **Practices:** Pharmacy-based interventions evaluated included patient counseling, prescription drug monitoring program monitoring, naloxone-based interventions, and referral to treatment resources

• **Outcomes:**
  - Pharmacists and patients view the use of patient counseling and prescription drug monitoring program validation of prescriptions as acceptable opioid-misuse interventions
  - Patients expressed interest in naloxone-based interventions while many pharmacists were opposed


• **Design:** Observational evaluation of opioid use outcomes

• **Practices:** Interdisciplinary ED opioid reduction task force was formed by emergency medicine and toxicology clinical pharmacy specialists. Primary goals were to reduce overall opioid use in adult and pediatric EDs and opioid discharge prescriptions by 30% over 12-months; developed documents including opioid prescribing guideline and disease state-specific treatment pathways for multimodal pain management, pain management for patients with opioid dependence, and treatment of opioid withdrawal and naloxone prescribing with standard phrases and talking points.

• **Outcomes/Conclusions:** clinical pharmacist-led ED opioid reduction program demonstrated positive results, with 63.5% reduction in overall ED opioid orders and significant decrease in monthly ED opioid orders per 1,000 visits at 12 months


• **Design:** Prospective survey study

• **Practices:** Pharmacists offered and provided education on opioid use disorder and naloxone to individuals attending community outreach events.
• **Outcomes/Conclusions:** of N=265 participants given naloxone spray, 21.5% (n=57) completed both initial and 3-month follow-up surveys; approximately 3.5% (n=2) of survey respondents reported utilizing naloxone which was dispensed. A total of 52.6% of respondents believed the naloxone initiatives decreased stigma of illicit opioid use.

Hoefling AD, et al. Impact of pharmacist contact via telephone vs letter on rate of acquisition of naloxone rescue kits by patients with opioid use disorder. Substance Abuse. 2020; 1-5.*

• **Design:** Retrospective study

• **Practices:** Mental health clinical pharmacy specialists (CPS) at VA St. Louis HCS aimed to increase distribution of naloxone rescue kits to patients with Opioid Use Disorder (OUD). Study groups included those contacted by letter alone and those contacted by both letter and phone call.

• **Outcomes/conclusions:**
  - N= 335 patients were included
  - N=185 patients targeted for phone follow-up, n=81 were reached (43.8%), and n=254 received the letter alone.
  - The primary outcome was achieved by n=13 (5.1%) and n=52 (64.2%) participants in the letter alone and letter plus phone contact groups, respectively (p < 0.001).
  - Non-white race, prior participation in rehabilitation and active opioid prescription were also associated with a higher rate of kit obtainment.


• **Design:** Descriptive report – academic detailing program to pharmacists on the topic of counseling and promoting naloxone to patients

• **Practices:** Pharmacists were recruited by convenience sampling. Three pharmacists who were experienced with academic detailing techniques provided the education. Survey data were collected to evaluate the program.

• **Outcomes/Conclusions:** 33 pharmacists participated who worked in a variety of ambulatory settings, including chain or corporate-owned pharmacies (58%), hospital-owned specialty pharmacies (15%), hospital-owned community pharmacies (15%), and independently owned or other pharmacies (12%). 28 (85%) completed an immediate post-session evaluation survey. 27 (96%) indicated they felt the information presented will impact their practice or patient care. 11 (33%) completed a second post-session survey, self-reporting improvements related to counseling patients about naloxone. Overall, participating in academic detailing supports community pharmacists’ providing patient counseling about naloxone.


• **Design:** Prospective quality improvement project

• **Practices:** The Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression (RIOSORD) tool was used to identify patients with risk class ≥4 who did not have a naloxone kit filled in the past year. Pharmacy trainees contacted at-risk patients and offered naloxone during a team-based telephone outreach event.

• **Outcomes/Conclusions:**
There was a statistically significant increase in the proportion of at-risk patients who had a naloxone kit before versus after the event (difference = 0.35, p < 1 × 10⁻⁶). Per-protocol analysis showed that of 164 patients contacted, 67% were reached (n = 109) and 80 patients accepted naloxone, corresponding to a 73% acceptance rate for those reached. The average reported time spent on phone call and documentation per patient reached was 14 minutes. A team-based telephone outreach event is an effective method for distributing naloxone to at-risk outpatient veterans.


- **Design**: Descriptive review
- **Practices**: A pharmacist provided in-person consultation visit and optional follow-up visit for the assistance of chronic pain management in 2 primary care practices over 4 month period. Eligible patients had chronic pain and a long-term prescription for opioids or buprenorphine or were referred by their primary care physician (PCP)
- **Outcomes/conclusions**:
  - n=46 of N=182 eligible patients completed all follow-up with n=43 (91%) receiving opioids over the past 6 months.
  - Pharmacist recommended adding or switching to a nonopioid pain medication (n=30), switching to buprenorphine for pain and complex persistent opioid dependence (n=20), and tapering opioids (n=3).
  - All physicians found the intervention acceptable and wanted more guidance on prescribing buprenorphine for pain.


- **Design**: Descriptive Report- SBIRT (screening, brief intervention, and referral to treatment) and naloxone training and pre-post survey results
- **Practices**: Twenty-four pharmacists in Philadelphia, PA completed SBIRT and naloxone trainings. Each pharmacy had at least 1 pharmacy champion who received additional training on and helped develop pharmacy site-specific naloxone dispensing protocols
- **Outcomes/Conclusion**: Pre-post survey results showed a reduction in stigmatizing attitudes regarding naloxone dispensing; an increase in understanding of the standing order and appropriate naloxone use; and an increase in self-reported confidence in ability to appropriately identify, discuss, and dispense naloxone to patients. All pharmacies increased their average monthly dispensing rate following protocol implementation. Pharmacists who received both trainings were more likely to change naloxone dispensing practices and increase dispensing in community pharmacies.


- **Design**: Care gap evaluation via retrospective chart review in a community pharmacy setting within an academic medical center
- **Practices**: 


![VA Logo](image-url)
Pharmacist identified patients from a rheumatology clinic prescribed at least 1 opioid medication and >1 short acting opioid, >90 MMED, >7-day supply of medication, and/or inappropriate medication combinations; gaps identified included minimal documentation of risk mitigation strategies and absence of naloxone. N=11 patients seen by pharmacist prior to clinic appointment; interventions included comprehensive assessment of presenting problem and recommendations to provider, PDMP search and mood evaluation, medication and naloxone education, and evaluation of lab needs.

Outcomes/Conclusions: community pharmacists can engage patients and providers to fill care gaps for high risk patients and optimize pain management; untreated depression, anxiety, and insomnia were the most common problems identified by pharmacists.

Bingham JM, Taylor AM, Boesen KP. Preliminary investigation of pharmacist-delivered, direct-to-provider interventions to reduce co-prescribing of opioids and benzodiazepines among a Medicare population. Pharmacy. 2020;8:25.

• Design: Retrospective review of prescription claims data
• Practices: Medication therapy management (MTM) tele-pharmacists identified patients with concurrent prescriptions for opioids and benzodiazepines via prescription claims data and provided recommendation to prescriber to discontinue one of the co-prescribed drugs.
• Outcomes/Conclusions: 37,990 (65.79%) of pharmacist interventions resulted in a medication discontinuation by the provider. Top medications discontinued included hydrocodone/APAP, alprazolam, and tramadol; initial evidence supports pharmacist-supported direct-to-prescriber programs as an effective medication safety strategy.


• Design: prospective single-arm cohort QI intervention
• Practice: Many housing facilities for homeless veterans contracted with the San Francisco Veterans Affairs Health Care System are located in neighborhoods with high rates of opioid overdose. This quality improvement (QI) initiative aimed to increase provision of opioid overdose education and naloxone for veterans and staff at contracted housing facilities.
• Outcomes/Conclusions: A total of 18 contracted veteran housing programs were contacted from July 2019 through January 2020 to schedule training. Of those, 13 programs responded to outreach and 10 visits were completed at 8 housing facilities. Training was provided by pharmacist and nurse practitioner trainers to 26 staff members and 59 veterans. Naloxone was prescribed to 37 veterans. Overall, A pharmacist-led and nurse practitioner–led initiative was effective in increasing veteran and staff access to opioid overdose education and naloxone at >44% contracted veteran housing facilities.


• Design: Descriptive report
• Practices: A multidisciplinary team of experts including pharmacists developed the protocol, which included 5 steps: (1) patient screening, (2) order placement in the electronic health record (EHR), (3) a patient training video, (4) dispensing of naloxone kit, and (5) written discharge instructions. The naloxone kits were assembled, labeled to meet requirements for a prescription, and stored in an
automated dispensing cabinet. Two pharmacists, 30 attending physicians, 65 resident physicians, and 108 nurses were trained.

- **Outcomes/Conclusions**: In 8 months, 134 orders for take-home naloxone were entered and 117 naloxone kits were dispensed, (87.3% obtainment rate). The indication for take-home naloxone kit was heroin use for 61 patients (92.4%). Overall, POC naloxone distribution is feasible and yielded a rate of obtainment significantly higher than previous studies in which naloxone was prescribed.


- **Design**: Descriptive practice review
- **Summary**: National and provincial changes aimed at improving access to harm reduction programs catalyzed the creation of the opioid overdose prevention pharmacist position at Centre for Addiction and Mental Health (CAMH) in Canada. The pharmacist acted as the central developer and coordinator of key deliverables, including an opioid overdose risk assessment tool, and provided education and training across the organization. The pharmacist trained clinicians within outpatient addictions services, as well as inpatient units and other outpatient clinics. Benefits of this initiative have extended beyond CAMH, such that resources have been made available to other organizations and can be modified and adapted to suit their needs. The pharmacist continues to be available for consultation by other institutions for implementation advice and knowledge translation at a health-systems level.


- **Design**: Practice Research Report-Key findings from 4 distinct studies (multisite cross-sectional pharmacist survey; multistakeholder intervention planning project; multisite cross-sectional patient survey; small-scale randomized trial)
- **Practices**: Study results show development of evidence for the Brief Intervention Medication Therapy Management (BIMTM) model to detect and address patient opioid misuse. BIMTM is an intervention consisting of 9 sessions. One medication management session is delivered in person by a community pharmacist, and the remaining sessions are delivered telephonically by a patient navigator to follow on goals established and address concomitant health concerns that increase risk for misuse.
- **Outcomes/Conclusion**: Overall, the establishment of BIMTM supports community pharmacist identification and intervention with patients engaged in opioid misuse


- **Design**: Descriptive report – Quality improvement project
- **Practices**: A quality improvement project was conducted to evaluate the number of pharmacist-provided opioid risk mitigation recommendations implemented by orthopedic providers for patients who underwent total hip or knee arthroplasty at SFVHCS. A pharmacist-led workflow for completing risk mitigation reviews was developed in collaboration with orthopedic providers, and urine drug screening was added to the preoperative laboratory testing protocol. The following recommendations were communicated via electronic medical record: limit postoperative opioids to a 7- or 14-day supply based
on risk of suicide and/or overdose, offer naloxone and a medication disposal bag, and order a urine drug screen if not already completed.

- **Outcomes/conclusion**: Risk reviews were completed for 75 patients. Among 64 patients with 2-month post-discharge data available, 88% (7 of 8) of 7-day and 79% (44 of 56) of 14-day opioid supply recommendations were implemented; 41% (26 of 59) of recommendations to issue a medication disposal bag, 17% (2 of 12) recommendations to order a missing urine drug screen, and 9% (5 of 55) of recommendations to offer naloxone were implemented.


- **Design**: Descriptive Report-Implementation of a system-wide Opioid Steering Committee at a nonprofit Catholic health system

- **Practices**: The committee was chaired by a senior pharmacy executive and supported by 4 subcommittees: data analytics, education development, outreach and assessment, and electronic health record (EHR). The committee developed and implemented several initiatives, including forming a database with prescribing data by specialty and geographical location, implementing a standardized screening approach in the emergency department, challenging hospitals to create partnerships with local schools, and creating EHR enhancements to change opioid prescribing habits.

- **Outcomes/Conclusion**: The prescribed opioid burden was reduced from 65.3 to 35.2 morphine milligram equivalents (MME) from 2016 to 2019 (46% absolute reduction). During this same time the number of acute prescription orders with a MME dose >30 was reduced by 52% (from 37,793 to 17,822 prescriptions per year).


- **Design**: descriptive review of implementation of a pharmacist-driven pain management service for inpatients with concomitant substance use disorder

- **Practices**: Clinical pharmacists provided pain pharmacotherapy recommendations with a goal of adequate pain management and behavior modification (preferentially prescribing patient-controlled analgesia (PCA), oral opioids, or non-opioid alternatives)

- **Outcomes**:  
  - End of 3-month pilot period: a significant reduction of 25% in intermittent morphine and 42% in intermittent hydromorphone use (month prior vs. pilot conclusion); increase frequency of PCAs use (n=3 vs. n=12) in the month prior to and concluding implementation.
  - All team members surveyed noted decreased intravenous intermittent opioid use corresponding with decrease in disruptive and intimidating behavior.


- **Design**: Descriptive Study

- **Practices**: Based on needs' assessment findings, a pharmacist-led academic detailing program was designed to provide education and resources for community pharmacies. The project sought to assess current practice and needs and address pharmacists' skills in managing patients with opioid use disorder
(OUD) and/or at risk for overdose. Visits were scheduled in high-risk regions. Coaching and materials were provided.

- **Outcomes:**
  - Total pharmacies visited = 136
  - Resources: 86.8% stocked naloxone; 94.9% stocked mOUD; 64% would sell syringes per state law; 57% provided all of these services
  - Needs: 27.9% had naloxone signage/handouts; 22.1% had supplemental materials; 25% had referral information
  - Barriers: providing resources/help, financial issues, stigma, transportation


- **Design:** Cross-sectional
- **Practices:** Assessment of the differences in rates of naloxone dispensing from retail pharmacies in states that authorize pharmacist prescription of naloxone and states that do not

**Outcomes:**
- The presence of state laws authorizing pharmacists to prescribe naloxone is associated with an average increase of 331 (95% CI 43.56, 618.49) prescriptions dispensed per state per quarter
- Approximately 53% increase in naloxone dispensed compared to pharmacies in states where pharmacists were not able to prescribe naloxone


- **Design:** Prospective 4-month interventional study
- **Practices:** Intervention at 5 large community chain pharmacies. A pharmacist recommended naloxone to any patient filling opioid prescription without naloxone per generated report at the point of care. Patients who accepted received pharmacist counseling from a standardized script and by using a naloxone nasal spray demo kit. Patients then took a post-intervention survey.

**Outcomes:**
- 121 naloxone prescriptions were dispensed; 36% increase compared to previous year
- 38 patients completed survey: indicated being very confident with administering naloxone correctly (73.9%) and for recognizing opioid overdose (65.2%)
  - Of patients who completed the survey, 60.5% received naloxone and accepted counseling from the pharmacist


- **Design:** Online anonymous survey sent to all pharmacists with an active license registered with the North Carolina State Board of Pharmacy (NCBOP)
- **Practice:** North Carolina pharmacists were surveyed regarding harm reduction services, non-prescription syringe sales, naloxone dispensing, and HIV/HCV screening
• **Conclusions**: Interventions to increase harm reduction services in North Carolina community pharmacies will need to target structural barriers, such as store policies, as well as individual pharmacists’ attitudes. Educational trainings for pharmacists that highlight the evidence of harm reduction interventions, opportunities to provide HIV/HCV screening, and the magnified impact of interventions offered by rural pharmacists are needed.


- **Design**: Descriptive report
- **Practice**: Pharmacist led initiative that used VA Academic Detailing dashboards to identify providers and patients that would benefit from outreach for education and implement facility-wide initiatives
- **Conclusions**: N=194 patients received a naloxone kit from the study facility in 2015; after the 2-year CPP driven initiative to promote overdose prevention education and naloxone distribution, the number of Veterans with a naloxone kit increased 9-fold to N=1725.


- **Design**: Cross-sectional, descriptive, survey-based study of community pharmacists
- **Practice**: Community pharmacists in North Carolina, Tennessee, and Virginia were surveyed on syringe dispensing behaviors, dispensing intentions, and perceptions of syringe dispensing legality in their practice state.
- **Outcomes/conclusions:**
  - 52.3% response rate across the 3 states (N=391)
  - North Carolina pharmacists had significantly higher number of past-30 day non-prescription syringe sales, less denial of non-prescription syringe requests, and decreased justification for syringe dispensing than Tennessee and Virginia pharmacists
  - Likely related to policies regarding pharmacists dispensing syringes to people who inject drugs.


- **Design**: descriptive review of program implementation
- **Practices**: three champion Veterans Affairs facilities in Danville, Illinois, Orlando, Florida, and San Francisco, California, worked to clarify legal considerations, address barriers, and implement syringe services programs integrated into the healthcare systems led by and in collaboration with clinical pharmacist practitioners
- **Conclusions:**
  - Collectively engaged approximately 400 Veterans, distributed nearly 10,000 syringes, 2,500 fentanyl test strips, 50 wound care kits, and 45 safer sex kits
  - Clinical pharmacist practitioners are uniquely poised to offer SSP services in clinical settings in collaboration with outreach staff
Policy & Position Statements


- **Resource type:** summary of professional meeting proceedings convened by Center for Substance Abuse Treatment (CSAT) and SAMHSA in partnership with National Institute on Drug Abuse (NIDA) with goal of gathering the perspectives of field experts regarding the state of practice and possible strategies for advancement.

- **Key findings:**
  - Strategies to increase access to buprenorphine included training pharmacists to take on additional responsibility related to buprenorphine treatment (e.g. medication monitoring and compliance)
  - Key work group conclusions related to role of provider in training in improving access included recommendation to “increase educational opportunities and resources for nonphysician stakeholders, especially pharmacists”


- **Resource type:** Professional organization position statement outlines specific substance abuse related activities in which pharmacists should be involved in a variety of patient care, employee health, and community activities

- **Summary:**
  - Pharmacists have the unique knowledge, skills, and responsibilities for assuming an important role in substance abuse prevention, education, and assistance.
  - Examples of responsibilities relevant to the SUD CPS include:
    - Promote substance abuse prevention efforts within healthcare organizations through employee education/awareness, participation in state prescription drug monitoring programs, and evaluation of practices which enable or foster drug abuse behavior.
    - Provide substance abuse education to healthcare professionals, healthcare trainees, and patients by fostering development of substance abuse related curricula for pharmacy students; providing post-graduate training in addictions, pain management, and palliative care to various healthcare disciplines; and conducting research on substance abuse and addiction.
    - Aid through identification and treatment referral for patients who may have signs of substance abuse; collaboration on development of pharmacotherapeutic elements of drug detoxification protocols; and provision of pharmaceutical care to patients treated for substance abuse and dependency.


- **Resource type:** Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) Core Competencies for Pharmacists

- **Summary:** Key concepts, skills, and attitudes are outlined to optimize, sustain, and expand independent and collaborative pharmacist roles in caring for persons who use and misuse substances and those diagnosed with substance use disorder

West Virginia Board of Pharmacy Guideline: Pharmacists and Buprenorphine-Assisted Therapy. Sep 2017; Charleston, WV

- **Resource type:** state board of pharmacy practice guideline
• **Summary:** includes standards and responsibilities to guide pharmacists in dispensing buprenorphine for opioid use disorder in accordance with state, local, and federal laws and regulations with an emphasis to expanding access to safe and effective treatment.


• **Resource type:** state legislative report ordered after pharmacists were granted provider status per state Act 173 (2016)

• **Summary:** outlines existing evidence and uncertainties related to the pharmacist role in prevention of opioid misuse, abuse, and diversion and whether and to what extent pharmacists should be reimbursed for certain clinical services

**Editorial/Commentary**


• **Resource type:** editorial/commentary

• **Summary:**

  - Call to revise antiquated laws and health-systems policies which restrict prescribing for various disciplines and improve approach to regulating health professionals’ scope of practice to better serve needs of patients
  - “Psychiatric pharmacists, for example, could help offset the shortage of psychiatrists by providing medication-management services...many states don’t allow these practitioners to prescribe buprenorphine, despite the need for more trained clinicians to mitigate the opioid epidemic.

*Green T, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment. Substance Abuse. 2020; 41:2, 147-149, DOI: 10.1080/08897077.2020.1752351*

• **Resource type:** editorial/commentary

• **Summary:** interprofessional authors “highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic” and specifically address the impact of the pandemic on persons with substance use disorder, barriers that persist, and considerations for easing regulations which impede care


• **Resource type:** editorial/commentary

• **Summary:** Pharmacist authors highlight the potential role of leveraging pharmacists during the opioid/COVID-19 syndemic to improve medication access and outcomes for OUD. Pharmacists, while both qualified and capable of liberalizing access to all forms of MOUD, may have the strongest impact by increasing access to buprenorphine. Pharmacists can be utilized in a variety of settings to help provide strategies for increasing access and use of MOUD within the inpatient, community, as well as the outpatient and transitions of care setting. Strategies should continue to be identified to increase patient access to MOUD, particularly buprenorphine, with increased clinical pharmacist utilization.

- **Design**: commentary
- **Practices**: The accessibility of pharmacists and their knowledge of commonly abused substances, including prescription medications, make them a practical yet underutilized provider for conducting substance use screening, intervention, and referring to care in the community.
- **Outcomes/Conclusions**:
  - Rural pharmacists currently report providing more public health services than their urban counterparts (i.e. disease state management, identifying health risk, working with community partners to address health problems, and referring patients to other health professionals)
  - Retail clinics, churches, and pharmacies provide a currently underdeveloped opportunity for improving the availability of screening and brief counseling and linkage of rural substance users to more intensive substance use care


- **Resource type**: commentary
- **Summary**: description of integration and application of pharmacists as a collaborative provider for management of buprenorphine/naloxone for opioid use disorder at Minneapolis VA Health system and Cleveland Clinic at Akron General as presented by interprofessional group at the 2019 American Society of Health-system Pharmacists Midyear Clinical Meeting


- **Design**: Commentary
- **Practices**: Response of providers (e.g. physicians, advance-practice nurses, pharmacists) to COVID-19 and subsequent impact on their progress toward increasing adoption of mOUD
- **Outcomes/conclusions**:
  - Loosening of regulatory restrictions fostered accelerated adoption of mOUD
  - Rapid support for telehealth offered a mechanism to increase mOUD access
  - Reevaluation of current practices surrounding mOUD strengthened adoption
  - Overall, during the COVID-19 crisis, facilities and providers responded positively to the call for increased access to mOUD and appropriate care of patients with OUD


- **Design**: commentary
- **Practices**: description of the specific value and opportunity of Board-certified Psychiatric Pharmacists (BCPP’s) in expanding access, improving outcomes, and minimizing costs of care. The BCPP role in expanding and optimizing MOUD is highlighted.
- **Conclusion**: The National Council for Behavioral Health Medical Director Institute has recommended that the number of BCPP’s who are clinical pharmacists with advanced specialized training and
experience in the treatment of patients with psychiatric and substance use disorders be expanded to address the national shortage of behavioral health providers. This includes expanding access to MOUD which decrease morbidity, mortality, and increase treatment retention. The physician-pharmacist collaborative model has been cited as an innovative and feasible approach to MOUD management.


- **Design**: Descriptive literature review using PubMed, review of policies and programs using the federal register, DEA, HHS, SAMHSA, ACCP, and APhA websites
- **Practices**: Identified barriers to care for patients with OUD during the COVID-19 pandemic and explored opportunities for pharmacists to improve OUD care during the pandemic and beyond.
- **Conclusions**: Roles for pharmacists include OUD risk identification and screening, referral of patients to treatment and support programs, ensuring medication access, expanding naloxone access, and advocacy initiatives. Practice changes, pharmacist and patient education, elimination of biases toward OUD care, and advocacy efforts are key for pharmacists to better serve this vulnerable population.